APA (7th ed.) Citation

CL, O., MR, B., AD, Ø., SK, S., VH, D., P, K., . . . K, G. (2022). Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(24), 5306. https://doi.org/10.1158/1078-0432.CCR-22-1810

Chicago Style (17th ed.) Citation

CL, O'Connell, et al. "Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 28, no. 24 (2022): 5306. https://doi.org/10.1158/1078-0432.CCR-22-1810.

MLA (9th ed.) Citation

CL, O'Connell, et al. "Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 28, no. 24, 2022, p. 5306, https://doi.org/10.1158/1078-0432.CCR-22-1810.